Commentary on: Assessing surrogates as trial endpoints using mixed models

Statistics in Medicine

Volumn 24, Issue 2, 2005, Pages 183-185

  Korn, E L ^b   Albert, P S ^b   McShane, L M ^b   Freedman, Laurence ^a  

^a BAR ILAN UNIVERSITY   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PLACEBO; ZIDOVUDINE;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL STUDY; CLINICAL TRIAL; FEMALE; HUMAN; MEDICAL RESEARCH; METHODOLOGY; OVARY CANCER; STATISTICAL ANALYSIS; STATISTICAL MODEL; CLINICAL PROTOCOL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOTE;

CLINICAL PROTOCOLS; CLINICAL TRIALS; HIV INFECTIONS; HUMANS; MODELS, STATISTICAL;

EID: 17144418988     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1857     Document Type: Article

References (3)

1. Korn EL, Albert PS, McShane LM. Assessing surrogates as trial endpoints using mixed models. Statistics in Medicine 2005; 24 2):163-182.
2. Torri V, Simon R, Russek-Cohen E, Midthune D, Friedman M. Statistical model to determine the relationship of response and survival in patients with advanced ovarian cancer treated with chemotherapy. Journal of National Cancer Institute 1992; 84:407-414.
3. Daniels MJ, Hughes MD. Meta-analysis for the evaluation of potential surrogate markers. Statistics in Medicine 1997; 16 1965-1982.